[New Year's Message] Song Young-sook, Chairman of Hanmi Group, "Breaking Old Habits, Reorganizing Displays for Global Expansion"

Song Young-sook, Chairwoman of Hanmi Pharmaceutical Group, urged, "Let's break away from the old framework and reorganize the display to move forward vigorously on a global scale."

Song Young-sook, Chairwoman of Hanmi Pharmaceutical Group. Photo by Yonhap News

In her New Year's address on the 2nd, Chairwoman Song pointed to the development of the obesity treatment pipeline, including 'Epeglenaide,' as last year's achievement, stating, "It showed the direction Hanmi Pharmaceutical should take."

She went on to report that in the domestic business sector, the combination drug for dyslipidemia, 'Rosuzet,' ranked first in domestic outpatient prescriptions for seven consecutive years.

In the overseas business sector, she mentioned the export of finished products to the Middle East region, and in the research and development (R&D) sector, she highlighted development achievements such as the glucagon-like peptide-1 (GLP-1)-based obesity treatment drug Epeglenaide.

Meanwhile, there is an analysis that the 'four-party alliance,' including Chairwoman Song, reached an agreement last December with Lim Jong-yoon, the eldest son of the late founder of Hanmi Pharmaceutical Group, Lim Sung-gi, who is an inside director, bringing the end of the year-long management rights dispute closer.

This content was produced with the assistance of AI translation services.